<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975674</url>
  </required_header>
  <id_info>
    <org_study_id>213CEIH2016</org_study_id>
    <nct_id>NCT02975674</nct_id>
  </id_info>
  <brief_title>Evaluation of MT-12 Implant Survival and Marginal Bone Loss</brief_title>
  <acronym>213CEIH2016</acronym>
  <official_title>Evaluation of MT-12 Implant Survival and Marginal Bone Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad de Granada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is designed as a consecutive enrollment prospective one-center study. A minimum of
      30 patients will be included in the study. At implant installation, the patient will be
      randomized to receive one of the two types of implants (Control: internal hexagon connection
      implants (CON.INT); Test: Morse taper connection implants (MT-12)). Samples of peri-implant
      crevicular fluid (PICF) and intrasulcular plaque will be collected at -21 (second-stage
      surgery), -14 (impressions), 0 (Baseline: prosthesis delivery), 7 days and 1, 3, 6, 12
      months. Prosthesis will be fabricated and delivered as usual, i.e., approximately two weeks
      after the impressions are taken.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marginal bone level</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peri-implant inflammation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-implant microbial contamination</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Jaw, Edentulous, Partially</condition>
  <arm_group>
    <arm_group_label>MT-12 dental implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MT-12 dental implant with Morse taper implant-abutment connection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CON.INT dental implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CON.INT dental implant with internal hexagon implant-abutment connection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MT-12 dental implant</intervention_name>
    <description>Placement of the MT-12 dental implant with Morse taper implant-abutment connection</description>
    <arm_group_label>MT-12 dental implant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CON.INT dental implant</intervention_name>
    <description>Placement of the CON.INT dental implant with internal hexagon implant-abutment connection</description>
    <arm_group_label>CON.INT dental implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt;18 and ≤75 years old

          -  One missing tooth in the premolar or molar area with both opposing and adjacent teeth
             (mesial and distal)

        Exclusion Criteria:

          -  One-stage bone augmentation

          -  Uncontrolled type 1 or 2 diabetes (HgA1c&gt;8)

          -  Known auto-immune or inflammatory disease

          -  Severe hematologic disorders, such as hemophilia or leukemia

          -  Local or systemic infection that may compromise normal healing (e.g., extensive
             periapical pathology)

          -  Liver or kidney dysfunction/failure

          -  Currently receiving cancer treatment or within 18 months from completion of radio- or
             chemotherapy

          -  Long-term history of oral bisphosphonates use (i.e., 10 years or more)

          -  History of intravenous bisphosphonates

          -  Long-term (&gt;3 months) history of antibiotics or drugs known to alter the inflammation
             and/or immunological system 3 months before inclusion

          -  Severe osseous diseases (e.g., Paget disease of bone)

          -  Pregnant women or nursing mothers

          -  Not able or not willing to follow instructions related to the study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Galindo-Moreno, DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Granada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facultad de Odontología</name>
      <address>
        <city>Granada</city>
        <zip>18071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Galindo-Moreno P, Fernández-Jiménez A, O'Valle F, Monje A, Silvestre FJ, Juodzbalys G, Sánchez-Fernández E, Catena A. Influence of the crown-implant connection on the preservation of peri-implant bone: a retrospective multifactorial analysis. Int J Oral Maxillofac Implants. 2015 Mar-Apr;30(2):384-90. doi: 10.11607/jomi.3804.</citation>
    <PMID>25830399</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Granada</investigator_affiliation>
    <investigator_full_name>Pablo Galindo-Moreno</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
    <mesh_term>Jaw, Edentulous, Partially</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

